Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.06−0.03 (-2.75%)
Close on Nov 18, 2026Market cap $282.13MP/E –Yield –
Autolus Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Autolus Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -238.7%. For fiscal 2025 it was -381.4%, against -2180.5% the year before. The highest annual figure on record is -381.4% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -381.4% | +1799.1 |
| FY2024 | Dec 31, 2024 | -2180.5% | +10091.8 |
| FY2023 | Dec 31, 2023 | -12272.3% | −9091.7 |
| FY2018 | Sep 30, 2018 | -3180.6% | −2015.4 |
| FY2017 | Sep 30, 2017 | -1165.2% | −129.7 |
| FY2016 | Sep 30, 2016 | -1035.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -85.6% | +143.4 |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -273.1% | +508.0 |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -371.9% | +94821.2 |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -373.3% | +148.8 |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -229.0% | +12137.5 |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -781.1% | +10155.7 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -95193.1% | −86354.9 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -522.1% | +3666.8 |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -12366.5% | −10639.7 |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -10936.9% | −7679.7 |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -8838.2% | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -4188.9% | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -1726.9% | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -3257.1% | – |
See a number that looks wrong?